Advertisement

PharmacoEconomics & Outcomes News

, Volume 832, Issue 1, pp 31–31 | Cite as

Shingrix cost effective versus Zostavax in Canada

Clinical study

Reference

  1. McGirr A, et al. Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults. Applied Health Economics and Health Policy : 28 Jun 2019. Available from: URL: https://doi.org/10.1007/s40258-019-00491-6

Copyright information

© Springer International Publishing AG 2019

Personalised recommendations